SCHEDULE: State Street Discloses 5.3% Stake in BioCryst Pharma

State Street Corporation has reported a 5.3% beneficial ownership stake in BioCryst Pharmaceuticals Inc. common stock as of December 31, 2025.

Summary

• State Street Corporation, a Massachusetts-based financial services company, has filed a Schedule 13G indicating beneficial ownership of BioCryst Pharmaceuticals Inc. common stock.
• As of December 31, 2025, State Street Corporation beneficially owns 11,073,211 shares of BioCryst Pharmaceuticals Inc. common stock.
• This ownership represents 5.3% of the total class of securities.
• State Street Corporation holds shared voting power over 10,457,690 shares and shared dispositive power over 11,073,211 shares.
• The filing was made by State Street Corporation as a parent holding company, with several of its investment adviser subsidiaries identified as acquiring the securities, including SSGA Funds Management, Inc. and State Street Global Advisors entities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While a Schedule 13G is a factual disclosure of ownership and not a performance report, the establishment of a significant passive stake by a major institutional investor like State Street Corporation can signal underlying confidence in the issuer.

Positives

• The disclosure of a significant passive stake by a major institutional investor like State Street Corporation can be viewed as a positive signal of institutional confidence in BioCryst Pharmaceuticals Inc.

Negatives

• The filing itself does not contain any negative information regarding BioCryst Pharmaceuticals Inc.'s performance or outlook.

Risks

• The filing does not disclose specific risks related to BioCryst Pharmaceuticals Inc.'s operations or financial health.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding BioCryst Pharmaceuticals Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that the disclosure of a significant passive stake by a major asset manager like State Street Corporation is a common occurrence in the financial markets. Such filings indicate that institutional funds are allocating capital to the company, which can be interpreted as a vote of confidence in the company's long-term prospects within the biotechnology and pharmaceutical sector. This type of institutional interest often attracts further scrutiny from other investors.

Comparison to Industry Standards

• Institutional ownership levels for biotechnology companies can vary widely, but a 5.3% stake by a prominent asset manager like State Street Corporation is a notable position, indicating a significant allocation within their managed portfolios.
• Compared to other pharmaceutical companies, a 5%+ institutional stake is generally considered a healthy level of institutional interest, suggesting that the company meets certain investment criteria for large-scale passive or index-tracking funds.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity, as large institutional holdings can stabilize a company's stock price and signal long-term interest.

Key Dates

Keywords

BioCryst Pharmaceuticals, State Street Corporation, Institutional Ownership, Schedule 13G, Common Stock, Beneficial Ownership, Pharmaceuticals, Investment Advisers